Potential Beneficial Effects of Resveratrol
|ClinicalTrials.gov Identifier: NCT01150955|
Recruitment Status : Completed
First Posted : June 25, 2010
Last Update Posted : March 22, 2012
|Condition or disease||Intervention/treatment|
|Metabolic Syndrome Obesity||Dietary Supplement: Resveratrol Other: Placebo|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Potential Beneficial Effects of Resveratrol on Obesity, Metabolic Syndrome and Inflammation - Emphasis on Description of the Molecular Biology Underpinning the Interplay Between Calorie Restriction, SIRT1, STAT5 and the GH/IGF-I Axis|
|Study Start Date :||October 2010|
|Primary Completion Date :||November 2011|
|Study Completion Date :||November 2011|
Active Comparator: Resveratrol
Dietary supplement of resveratrol 500 mg three times a day over five weeks.
Dietary Supplement: Resveratrol
500 mg three times a day for five weeks.
Other Name: Fluxome Sciences.
|Placebo Comparator: Placebo||
Placebo (starch capsules) 500 mg three times a day for five weeks.
Other Name: Starch
- Metabolic parameters [ Time Frame: Five weeks ]Regarding glucose, protein and fat metabolism.
- Pathways of substrate metabolism. [ Time Frame: Five weeks ]Description of the biochemical pathways underpinning the interplay between calorie restriction, SIRT1, STAT5 and the GH/IGF-I axis.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01150955
|Aarhus University Hospital, Department of Endocrinology, MEA|
|Aarhus, Denmark, 8000|
|Study Chair:||Jens Otto L Jørgensen, Professor,MD||Aarhus University Hospital|